Pharmacodynamic effect of cilostazol versus clopidogrel in stented patients during proton pump inhibitor co-administration: the ACCEL-PARAZOL study

Trial Profile

Pharmacodynamic effect of cilostazol versus clopidogrel in stented patients during proton pump inhibitor co-administration: the ACCEL-PARAZOL study

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel; Lansoprazole
  • Indications Cardiovascular disorders; Gastrointestinal disorders
  • Focus Pharmacodynamics
  • Acronyms ACCEL-PARAZOL
  • Most Recent Events

    • 17 Oct 2013 New trial record
    • 03 Sep 2013 Primary endpoint 'Platelet-aggregation' has not been met.
    • 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top